

## **Epidermal Growth Factor Receptor Targeted Doxorubicin and Vitexin Loaded Niosomes for Enhanced Breast Cancer Therapy**

S. Malathi<sup>1</sup>, Valappil Sisila<sup>2#</sup>, V. Singaravel<sup>3#</sup>, Nandakumar Venkatesan<sup>4,5</sup>, Iqbal Pakrudheen<sup>6,7</sup>,  
R. Dhanaraj<sup>3</sup>, Niraikulam Ayyadurai<sup>2</sup>, V. Bhuvaramurthy<sup>3</sup>, S. Narayana Kalkura<sup>1\*</sup>

<sup>1</sup>Crystal Growth Centre, Anna University, Guindy, Chennai 600025, India.

<sup>2</sup>Biochemistry & Biotechnology, CSIR-Central Leather Research Institute,  
Adyar, Chennai – 600020, India

<sup>3</sup>Department of Medical Biochemistry, Post-graduate Institute of Basic Medical Sciences,  
University of Madras, Taramani, Chennai 600113, India

<sup>4</sup>Department of Pediatrics, Obstetrics, and Gynaecology, University of Valencia, Valencia, 46010, Spain

<sup>5</sup>Sri Ramachandra Faculty of Engineering and Technology, Sri Ramachandra Institute of Higher Education and  
Research, Chennai 600116, India

<sup>6</sup>Department of Chemistry, CMR Institute of Technology, Bengaluru 560037, India

<sup>7</sup>Centre of Excellence- Sensors & Nanoelectronics, CMR Institute of Technology, Bengaluru 560037, India

# Equal contribution




Figure S1. Kinetics of drug release of NIOD formulations (A) Zero order; (B) First order; (C) Higuchi model; (D) Korsmeyer - Peppas model; (E) Hixson Crowell model




Figure S2. Kinetics of drug release of NIOV formulations (A) Zero order; (B) First order; (C) Higuchi model; (D) Korsmeyer - Peppas model; (E) Hixson Crowell model




Figure S3. Kinetics of drug release of NIODV formulations (A) Zero order; (B) First order; (C) Higuchi model; (D) Korsmeyer - Peppas model; (E) Hixson Crowell model




Figure S4. FDA/PI staining assay of niosome induced apoptosis in MDA-MB-231 cells.